Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Nakouzi, Nader Al; Moulec, Sylvestre Le; Albigès, Laurence; Wang, Chris Kedong; Beuzeboc, Philippe; Gross‐Goupil, Marine; Rouge, Thibault De La Motte; Guillot, Aline; Gajda, Dorota; Massard, Christophe; Gleave, Martin; Fizazi, Karim; Loriot, Yohann

doi:10.1016/j.eururo.2014.04.015

Cited by 156 publications

(124 citation statements)

References 27 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…In vitro studies had shown that cabazitaxel was able to decrease cell viability in both enzalutamide-resistant and enzalutamide-sensitive cells, but abiraterone did not show the same decrease in cell viability following enzalutamide. 12 It appears that cabazitaxel has its effects on prostate cancer cells mainly via pathways independent of the androgen receptor, which could reduce the cross-resistance phenomenon observed with hormonal therapies. 12 This would be a viable explanation as to why prior abiraterone did not impact cabazitaxel efficacy; and similar PSA responses were reported in other studies when cabazitaxel was used post-hormonal therapies in mCRPC patients.…”

mentioning

confidence: 99%

“…12 It appears that cabazitaxel has its effects on prostate cancer cells mainly via pathways independent of the androgen receptor, which could reduce the cross-resistance phenomenon observed with hormonal therapies. 12 This would be a viable explanation as to why prior abiraterone did not impact cabazitaxel efficacy; and similar PSA responses were reported in other studies when cabazitaxel was used post-hormonal therapies in mCRPC patients. 12,13 In conclusion, this EAP study, although limited by its small sample size, provides additional data on the efficacy and safety of cabazitaxel in mCRPC patients previously treated with docetaxel, with or without prior abiraterone use.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone

Saad¹,

Winquist²,

Hubay³

et al. 2016

CUAJ

View full text Add to dashboard Cite

Introduction: In the TROPIC study, cabazitaxel improved overall survival in abiraterone-naïve metastatic castration-resistant prostate cancer (mCRPC) patients post-docetaxel. To evaluate cabazitaxel in routine clinical practice, an international, single-arm trial was conducted. Efficacy, safety, and quality of life (QoL) data were collected from Canadian patients enrolled. Overall survival and progression-free survival were not collected as part of this study. Importantly, prior abiraterone use was obtained and its impact on clinical parameters was examined. Methods: Sixty-one patients from nine Canadian centres were enrolled, with prior abiraterone use known for 60 patients. Prostatespecific antigen (PSA) response rate, safety, and impact on QoL life were analyzed as a function of prior abiraterone use. Results: Overall, 92% of patients were ECOG 0/1, 88% had bone metastases, and 25% visceral metastases. Patients treated without prior abiraterone (NoPriorAbi) (n=35, 58%) and with prior abiraterone (PriorAbi) (n=25, 42%) had similar baseline characteristics, except for age and prior cumulative docetaxel dose. Median number of cabazitaxel cycles received was similar between groups (NoPriorAbi=6, PriorAbi=7), as was PSA response rate (NoPriorAbi=36.4%, PriorAbi=45.0%, p=0.54). Almost one-third (31%) of patients received prophylactic granulocyte colony-stimulating factors. Most frequent Grade 3/4 toxicities were neutropenia (14.8%); anemia, febrile neutropenia, fatigue (each at 9.8%); and diarrhea (8.2%). No treatment-related adverse event leading to death was observed. QoL and pain were improved with no difference seen between groups. Treatment discontinuation was mainly due to disease progression (45.9%) and adverse events (32.8%). Conclusions:In routine clinical practice, cabazitaxel's risk-benefit ratio in mCRPC patients previously treated with docetaxel seems to be maintained independent of prior abiraterone use.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone

Saad¹,

Winquist²,

Hubay³

et al. 2016

CUAJ

View full text Add to dashboard Cite

show abstract

“…68 Furthermore, a promising study has recently shown that cabazitaxel remains active as a third-line agent even after first-line docetaxel and second-line AA treatment. 69 Taken into consideration with the results of the CHAARTED trial, in which early docetaxel administration was shown to significantly improve OS in combination with ADT in the setting of non-mCRPC, cabazitaxel may play a much more central role in the management of mCRPC.…”

Section: Resultsmentioning

confidence: 99%

Contemporary agents in the management of metastatic castration-resistant prostate cancer

Kapoor

Shayegan³

et al. 2016

CUAJ

View full text Add to dashboard Cite

Docetaxel-based chemotherapy has been the standard of care for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a significant paradigm shift in the treatment landscape of this disease. A deeper understanding of prostate cancer biology, along with the development of novel agents has created hope towards treating chemotherapy-naïve and resistant disease. Following the implementation of docetaxel as the first-line therapy for mCRPC, five novel therapies have demonstrated survival benefit in mCRPC. Cabazitaxel, abiraterone acetate, and enzalutamide are three agents recently approved for the treatment of mCRPC, having shown overall survival benefit in patients previously treated with docetaxel, while both abiraterone acetate and enzalutamide have also shown promise in the pre-docetaxel setting. Sipuleucel-T has shown overall survival benefit in asymptomatic mCRPC, while radium-223 provides survival benefit to patients with mCRPC who are symptomatic from their skeletal metastases in both docetaxel-naïve patients and post-docetaxel patients. Denosumab, an anti-RANKL antibody, has been approved for the prevention of skeletal-related events in patients with prostate cancer bone metastases. This review examines the phase 3 trials supporting the use of theses novel agents in the treatment of mCRPC. While these agents provide incremental increases in patient survival, further study to determine the best choice, combination, and/or sequencing of administration is still necessary.

show abstract

“…Concordante con esta evidencia, series clínicas han demostrado menores tasas de respuesta a docetaxel en pacientes previamente tratados con hormonoterapia de segunda generación 65,67 . Sin embargo, este fenómeno no ha sido observado aún con cabazitaxel [68][69][70] . El corolario de esta evidencia se resume en que la terapia inicial del CPmRC podría comprometer las tasas de respuesta a los tratamientos de segunda y tercera línea.…”

Section: Futuro: Secuenciación Y/o Sinergiaunclassified

Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales

Berlín

Fernández

2015

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Cited by 156 publications

References 27 publications

Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone

Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone

Contemporary agents in the management of metastatic castration-resistant prostate cancer

Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales

Contact Info

Product

Resources

About